Developer docs
API playgroundTry for free, no card

Search company profiles

Secarna Pharmaceuticals

Full company profile

uuid00065tz

Namestring
Secarna Pharmaceuticals
Legal namestring
Secarna Pharmaceuticals GmbH & Co. KG
Websiteurl
secarna.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Secarna Pharmaceuticals GmbH & Co. KG is a privately held German biopharmaceutical company founded in 2015 and headquartered at the Innovation and Start-Up Centers Biotechnology (IZB) in Planegg/Martinsried, with a registered office in Marburg. The company focuses on the discovery and development of antisense oligonucleotide (ASO) therapeutics, including both single-stranded ASOs and siRNAs, with the stated aim of addressing targets that are difficult or impossible to drug with conventional small molecules or biologics. Its core technology is the AI-empowered OligoCreator® platform, which integrates third-generation locked nucleic acid (LNA) chemistry via the LNAplus™ sub-platform, a proprietary in-silico sequence selection pipeline called Oligofyer™, and the LNA-Vit(r)ox™ safety assay for early identification of immunostimulatory and off-target effects; the Oligofyer system has been trained on data from over 50 discovery projects and is continuously refined with wet-lab feedback to optimize hit rates in safety and efficacy screens.

Secarna operates a B2B partnership-driven business model rather than a commercial product model. The company generates revenue — or more accurately, near-term cash inflows — through research collaborations, option-to-license agreements, milestone payments, and in some cases equity or warrant components with pharmaceutical, biotech, and academic counterparties; named partners span Evotec, Denali Therapeutics, Achilles Therapeutics, Lipigon Pharmaceuticals, SciNeuro Pharmaceuticals, Sun Yat-sen University, Celanese, Orbit Discovery, Vect-Horus, Scenic Biotech, VERAXA Biotech, Protalix BioTherapeutics, and venture firm Curie.Bio. Beyond partnered programs, Secarna maintains a proprietary pipeline led by SECN-15, a first-in-class ASO targeting Neuropilin-1 (NRP1) for solid tumors that is in IND-enabling studies with a planned IND submission in 2026. Pricing and deal economics are not publicly disclosed and are negotiated case-by-case. The company has 11–50 employees and is led by CEO Konstantin Petropoulos (promoted October 31, 2024), CSO Frank Jaschinski, and CRO Richard Klar, with a Scientific Advisory Board that includes NRP1 biology co-discoverer Prof. Dario Vignali and a corporate Advisory Board chaired by former BioNTech and MorphoSys CFO Jens Holstein.

Short descriptiontext

Secarna Pharmaceuticals is a privately held German biopharmaceutical company that discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics through its AI-empowered OligoCreator® platform, serving pharmaceutical, biotech, and academic partners via licensing and co-development deals while advancing its proprietary lead program SECN-15 toward the clinic.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMartinsried, Germany
HQ citystring
Martinsried
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide discovery, oligonucleotide drug development, AI drug discovery platform, locked nucleic acid therapeutics, preclinical oligonucleotide research
Industry2 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antisense Oligonucleotide Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Collaboration Agreements
TypeLicensing Royalties
Description

Secarna generates revenue through strategic partnerships with pharmaceutical, biotech, and academic organizations. These arrangements typically involve technology access fees, research funding, milestone payments upon achievement of predefined success criteria, and warrants or equity stakes in partner companies.

secarna.com
2Co-development and Co-ownership
TypeProfessional Services
Description

Collaborative arrangements where Secarna and partners share discovery and development responsibilities, building co-owned pipelines with milestone and royalty structures.

secarna.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Secarna Pharmaceuticals discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics using its AI-empowered OligoCreator® platform, which combines innovative and proven delivery modalities with proprietary safety and efficacy testing systems. The company offers partnered drug discovery and co-development services to pharmaceutical, biotech, and academic organizations, while also advancing its own proprietary pipeline, including the lead clinical candidate SECN-15 targeting Neuropilin-1 (NRP1) for solid tumors. Secarna generates real lead candidates for partners within 6–12 months through single- or multi-asset collaboration agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • High hit rate in in vitro and in vivo safety and efficacy screens
+2 more records
Product overview1 text field

Secarna Pharmaceuticals offers a portfolio of proprietary AI-empowered drug discovery platforms centered on the OligoCreator® platform, which integrates the LNAplus™ antisense technology, Oligofyer™ bioinformatics selection system, and LNA-Vit(r)ox™ safety testing. The company develops proprietary antisense oligonucleotide therapeutics, with SECN-15 as its lead clinical candidate targeting NRP1 for solid tumors. Secarna provides partnered discovery services through its platforms and maintains over 20 discovery and development programs across immuno-oncology, inflammatory, fibrotic, cardiometabolic, CNS, and neuromuscular disease areas.

Product and service1 record
1OligoCreator®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Expansion of existing scientific and strategic collaboration. Secarna supports Curie.Bio in identifying oligonucleotide candidates for its portfolio company ventures using OligoCreator® platform. Curie.Bio is a $1.25B global venture capital firm helping founders discover and develop important new medicines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Combines Protalix's rare disease and biologics expertise with Secarna's AI-powered OligoCreator® platform. Protalix obtains exclusive option to license active compounds for clinical development and potential commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Discovery and co-development agreement to develop disease-modifying oligonucleotide therapy against a novel target. Leverages Scenic's Cell-Seq platform for target identification and Secarna's OligoCreator® for oligonucleotide discovery. Target is relevant for rare genetic disorders and broader disease conditions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-30
Description

Strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases. Combines Secarna's OligoCreator® platform with VERAXA's click chemistry conjugation technology. Aims to leverage targeted delivery advantages of AOCs to precisely modulate gene expression in disease-relevant cells while minimizing off-target effects.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-07-10
Description

Research collaboration to advance systemic delivery of RNA-targeted therapeutics for CNS disorders. Combines Secarna's OligoCreator® technology with Vect-Horus' VECTrans® platform to enable delivery across the blood-brain barrier. VECTrans® uses engineered peptide and VHH antibody vectors for receptor-mediated transport.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2024-05-28
Description

Collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics. Leverages Orbit's bead-based peptide display engine for identification and selection of cyclic peptides to pair with Secarna's ASO molecules. Expands targeted ASO capabilities beyond antibodies and GalNAc.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-03-20
Description

RNA research collaboration for long-acting antisense therapies using Celanese VitalDose® Drug Delivery Platform with Secarna's ASO discovery platform. Aims to develop ASO-eluting implants to reduce dosing frequency and improve patient outcomes.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-03-27
Description

Research and option agreement in the field of CNS diseases. Secarna applies its OligoCreator® platform to design ASO candidates for neurological targets.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2022-05-31
Description

Partnership for ANGPTL4-targeting antisense oligonucleotide (Lipisense) for treatment of elevated blood lipids. First ASO derived from Secarna's LNAplus™ platform to enter Phase I clinical study.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-11-10
Description

Research, option and license agreement to develop optimized T cell therapies. Secarna's LNAplus™ ASOs have potential to optimize personalized T cell therapies being developed by Achilles in immune oncology.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2020-12-11
Description

Cooperation to develop LNAplus™-based antisense oligonucleotides specifically suppressing expression of host factors essential to SARS-CoV-2 viral infection cycle. Targeting host factors avoids risk of virus evading treatment due to mutation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

Research and option agreement for antisense therapies in neurodegenerative diseases. Leverages Secarna's LNAplus™ ASO platform with Denali's blood-brain barrier Transport Vehicle (TV) technology. Expanded in October 2021 to include multiple new programs across range of indications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

Strategic partnership in antisense therapy with comprehensive long-term platform agreement. Co-owned LNAplus™-based antisense pipeline with shared discovery and development responsibilities. Expanded in September 2021 to include third-party discovery, research and development programs. Evotec sources LNAplus™ antisense technology through strategic partnership with Secarna.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The pioneer and largest antisense oligonucleotide (ASO) therapeutics company, with multiple approved drugs and a deep clinical pipeline across neurological, cardiovascular, and metabolic diseases. Direct comparison to Secarna on ASO chemistry platforms and partnership-driven business model.

TypeBroad incumbent
Description

Leading siRNA therapeutics company with approved products and broad pipeline, operating a discovery and partnership platform similar in concept to Secarna's OligoCreator. A broader incumbent in oligonucleotide therapeutics with deeper clinical pipeline and commercial revenues.

TypeDirect peer
Description

Clinical-stage oligonucleotide therapeutics company with PRISM platform for stereopure ASO/siRNA discovery and development, focused on neurological and rare diseases. Direct platform-based competitor with overlapping ASO chemistry focus.

TypeBroad incumbent
Description

siRNA platform company with broad delivery technology portfolio (TRiM™) and multiple partnered clinical programs across cardiometabolic, CNS, and oncology indications. Broader incumbent in oligonucleotide therapeutics with established pharma partnerships.

TypeDirect peer
Description

Clinical-stage company developing antisense oligonucleotides (TANGO platform) for genetic diseases, with lead program in Dravet syndrome. Direct ASO peer with similar partnership-friendly discovery approach and CNS delivery focus.

TypeDirect peer
Description

RNA therapeutics company developing Axiomer® platform for ADAR-mediated RNA editing and antisense oligonucleotides for rare diseases. Comparable platform-based ASO company with similar pipeline-stage economics.

TypeBroad incumbent
Description

Acquired by Novo Nordisk in 2021, Dicerna developed GalXC™ siRNA platform with multiple partnered programs in rare diseases and cardiometabolic indications. Now an internal oligonucleotide platform within a major pharma — relevant incumbent comparable.

TypeDirect peer
Description

Biotech developing BBB-crossing delivery vehicles (Transport Vehicle technology) for CNS-targeted therapeutics including ASOs. Secarna partner and a comparable developer of BBB-penetrant oligonucleotide therapies, partially overlapping in scope.

TypeRegional player
Description

German drug discovery and development contract research organization with co-owned LNAplus™ antisense pipeline via Secarna partnership. Operating from Hamburg, Evotec is a comparable regional player with significant exposure to the oligonucleotide discovery space.

TypeBroad incumbent
Description

Commercial-stage RNA therapeutics company focused on gene therapy and exon-skipping PMO chemistries for Duchenne muscular dystrophy. Broader incumbent in RNA-based therapeutics with established commercial products and delivery expertise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Secarna Pharmaceuticals

Antisense Oligonucleotide Drug Discoverysecarna.com

Secarna Pharmaceuticals is a privately held German biopharmaceutical company that discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics through its AI-empowered OligoCreator® platform, serving pharmaceutical, biotech, and academic partners via licensing and co-development deals while advancing its proprietary lead program SECN-15 toward the clinic.

What Secarna Pharmaceuticals does

Secarna Pharmaceuticals GmbH & Co. KG is a privately held German biopharmaceutical company founded in 2015 and headquartered at the Innovation and Start-Up Centers Biotechnology (IZB) in Planegg/Martinsried, with a registered office in Marburg. The company focuses on the discovery and development of antisense oligonucleotide (ASO) therapeutics, including both single-stranded ASOs and siRNAs, with the stated aim of addressing targets that are difficult or impossible to drug with conventional small molecules or biologics. Its core technology is the AI-empowered OligoCreator® platform, which integrates third-generation locked nucleic acid (LNA) chemistry via the LNAplus™ sub-platform, a proprietary in-silico sequence selection pipeline called Oligofyer™, and the LNA-Vit(r)ox™ safety assay for early identification of immunostimulatory and off-target effects; the Oligofyer system has been trained on data from over 50 discovery projects and is continuously refined with wet-lab feedback to optimize hit rates in safety and efficacy screens.

Secarna operates a B2B partnership-driven business model rather than a commercial product model. The company generates revenue — or more accurately, near-term cash inflows — through research collaborations, option-to-license agreements, milestone payments, and in some cases equity or warrant components with pharmaceutical, biotech, and academic counterparties; named partners span Evotec, Denali Therapeutics, Achilles Therapeutics, Lipigon Pharmaceuticals, SciNeuro Pharmaceuticals, Sun Yat-sen University, Celanese, Orbit Discovery, Vect-Horus, Scenic Biotech, VERAXA Biotech, Protalix BioTherapeutics, and venture firm Curie.Bio. Beyond partnered programs, Secarna maintains a proprietary pipeline led by SECN-15, a first-in-class ASO targeting Neuropilin-1 (NRP1) for solid tumors that is in IND-enabling studies with a planned IND submission in 2026. Pricing and deal economics are not publicly disclosed and are negotiated case-by-case. The company has 11–50 employees and is led by CEO Konstantin Petropoulos (promoted October 31, 2024), CSO Frank Jaschinski, and CRO Richard Klar, with a Scientific Advisory Board that includes NRP1 biology co-discoverer Prof. Dario Vignali and a corporate Advisory Board chaired by former BioNTech and MorphoSys CFO Jens Holstein.

Secarna Pharmaceuticals firmographics

Firmographics
Name
Secarna Pharmaceuticals
Legal name
Secarna Pharmaceuticals GmbH & Co. KG
Website
https://secarna.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Secarna Pharmaceuticals is a privately held German biopharmaceutical company that discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics through its AI-empowered OligoCreator® platform, serving pharmaceutical, biotech, and academic partners via licensing and co-development deals while advancing its proprietary lead program SECN-15 toward the clinic.
Ownership category
akta.pro rank

Secarna Pharmaceuticals industry classification

Industry
Product category
Antisense Oligonucleotide Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide discovery
  • Oligonucleotide drug development
  • AI drug discovery platform
  • Locked nucleic acid therapeutics
  • Preclinical oligonucleotide research

Where Secarna Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Martinsried
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Secarna Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and Collaboration Agreements: Secarna generates revenue through strategic partnerships with pharmaceutical, biotech, and academic organizations. These arrangements typically involve technology access fees, research funding, milestone payments upon achievement of predefined success criteria, and warrants or equity stakes in partner companies.
  2. Co-development and Co-ownership: Collaborative arrangements where Secarna and partners share discovery and development responsibilities, building co-owned pipelines with milestone and royalty structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Secarna Pharmaceuticals product offering

Product offering

Core offering

Secarna Pharmaceuticals discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics using its AI-empowered OligoCreator® platform, which combines innovative and proven delivery modalities with proprietary safety and efficacy testing systems. The company offers partnered drug discovery and co-development services to pharmaceutical, biotech, and academic organizations, while also advancing its own proprietary pipeline, including the lead clinical candidate SECN-15 targeting Neuropilin-1 (NRP1) for solid tumors. Secarna generates real lead candidates for partners within 6–12 months through single- or multi-asset collaboration agreements.

Product overview

Secarna Pharmaceuticals offers a portfolio of proprietary AI-empowered drug discovery platforms centered on the OligoCreator® platform, which integrates the LNAplus™ antisense technology, Oligofyer™ bioinformatics selection system, and LNA-Vit(r)ox™ safety testing. The company develops proprietary antisense oligonucleotide therapeutics, with SECN-15 as its lead clinical candidate targeting NRP1 for solid tumors. Secarna provides partnered discovery services through its platforms and maintains over 20 discovery and development programs across immuno-oncology, inflammatory, fibrotic, cardiometabolic, CNS, and neuromuscular disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • OligoCreator®

Quantifiable outcome

  • High hit rate in in vitro and in vivo safety and efficacy screens
  • +2 more outcomes

Companies that use Secarna Pharmaceuticals

Customer profile

Segments6 records

Ideal customer profiles2 records

Secarna Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Secarna Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and strategic.

  • Curie.BiocoreStrategic or Co-development Partner · 3 March 2026Expansion of existing scientific and strategic collaboration. Secarna supports Curie.Bio in identifying oligonucleotide candidates for its portfolio company ventures using OligoCreator® platform. Curie.Bio is a $1.25B global venture capital firm helping founders discover and develop important new medicines.
  • Protalix BioTherapeuticscoreStrategic or Co-development Partner · 17 December 2025Collaboration and option agreement to develop oligonucleotide therapies for rare renal indications. Combines Protalix's rare disease and biologics expertise with Secarna's AI-powered OligoCreator® platform. Protalix obtains exclusive option to license active compounds for clinical development and potential commercialization.
  • Scenic BiotechcoreStrategic or Co-development Partner · 23 October 2025Discovery and co-development agreement to develop disease-modifying oligonucleotide therapy against a novel target. Leverages Scenic's Cell-Seq platform for target identification and Secarna's OligoCreator® for oligonucleotide discovery. Target is relevant for rare genetic disorders and broader disease conditions.
  • VERAXA BiotechcoreStrategic or Co-development Partner · 30 September 2025Strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases. Combines Secarna's OligoCreator® platform with VERAXA's click chemistry conjugation technology. Aims to leverage targeted delivery advantages of AOCs to precisely modulate gene expression in disease-relevant cells while minimizing off-target effects.
  • Vect-HorusstrategicTechnology or Integration · 10 July 2025Research collaboration to advance systemic delivery of RNA-targeted therapeutics for CNS disorders. Combines Secarna's OligoCreator® technology with Vect-Horus' VECTrans® platform to enable delivery across the blood-brain barrier. VECTrans® uses engineered peptide and VHH antibody vectors for receptor-mediated transport.
  • Orbit DiscoverystrategicTechnology or Integration · 28 May 2024Collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics. Leverages Orbit's bead-based peptide display engine for identification and selection of cyclic peptides to pair with Secarna's ASO molecules. Expands targeted ASO capabilities beyond antibodies and GalNAc.
  • Celanese CorporationstrategicStrategic or Co-development Partner · 20 March 2024RNA research collaboration for long-acting antisense therapies using Celanese VitalDose® Drug Delivery Platform with Secarna's ASO discovery platform. Aims to develop ASO-eluting implants to reduce dosing frequency and improve patient outcomes.
  • SciNeuro PharmaceuticalsstrategicStrategic or Co-development Partner · 27 March 2023Research and option agreement in the field of CNS diseases. Secarna applies its OligoCreator® platform to design ASO candidates for neurological targets.
  • Lipigon PharmaceuticalsstrategicStrategic or Co-development Partner · 31 May 2022Partnership for ANGPTL4-targeting antisense oligonucleotide (Lipisense) for treatment of elevated blood lipids. First ASO derived from Secarna's LNAplus™ platform to enter Phase I clinical study.
  • Achilles TherapeuticsstrategicStrategic or Co-development Partner · 10 November 2021Research, option and license agreement to develop optimized T cell therapies. Secarna's LNAplus™ ASOs have potential to optimize personalized T cell therapies being developed by Achilles in immune oncology.
  • Sun Yat-sen UniversitystrategicStrategic or Co-development Partner · 11 December 2020Cooperation to develop LNAplus™-based antisense oligonucleotides specifically suppressing expression of host factors essential to SARS-CoV-2 viral infection cycle. Targeting host factors avoids risk of virus evading treatment due to mutation.
  • Denali TherapeuticscoreStrategic or Co-development Partner · 1 December 2020Research and option agreement for antisense therapies in neurodegenerative diseases. Leverages Secarna's LNAplus™ ASO platform with Denali's blood-brain barrier Transport Vehicle (TV) technology. Expanded in October 2021 to include multiple new programs across range of indications.
  • EvoteccoreStrategic or Co-development Partner · 1 December 2020Strategic partnership in antisense therapy with comprehensive long-term platform agreement. Co-owned LNAplus™-based antisense pipeline with shared discovery and development responsibilities. Expanded in September 2021 to include third-party discovery, research and development programs. Evotec sources LNAplus™ antisense technology through strategic partnership with Secarna.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Secarna Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Ionis Pharmaceuticals: The pioneer and largest antisense oligonucleotide (ASO) therapeutics company, with multiple approved drugs and a deep clinical pipeline across neurological, cardiovascular, and metabolic diseases. Direct comparison to Secarna on ASO chemistry platforms and partnership-driven business model.
  • Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with PRISM platform for stereopure ASO/siRNA discovery and development, focused on neurological and rare diseases. Direct platform-based competitor with overlapping ASO chemistry focus.
  • Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotides (TANGO platform) for genetic diseases, with lead program in Dravet syndrome. Direct ASO peer with similar partnership-friendly discovery approach and CNS delivery focus.
  • ProQR Therapeutics: RNA therapeutics company developing Axiomer® platform for ADAR-mediated RNA editing and antisense oligonucleotides for rare diseases. Comparable platform-based ASO company with similar pipeline-stage economics.
  • Denali Therapeutics: Biotech developing BBB-crossing delivery vehicles (Transport Vehicle technology) for CNS-targeted therapeutics including ASOs. Secarna partner and a comparable developer of BBB-penetrant oligonucleotide therapies, partially overlapping in scope.

Broad incumbents

  • Alnylam Pharmaceuticals: Leading siRNA therapeutics company with approved products and broad pipeline, operating a discovery and partnership platform similar in concept to Secarna's OligoCreator. A broader incumbent in oligonucleotide therapeutics with deeper clinical pipeline and commercial revenues.
  • Arrowhead Pharmaceuticals: siRNA platform company with broad delivery technology portfolio (TRiM™) and multiple partnered clinical programs across cardiometabolic, CNS, and oncology indications. Broader incumbent in oligonucleotide therapeutics with established pharma partnerships.
  • Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk in 2021, Dicerna developed GalXC™ siRNA platform with multiple partnered programs in rare diseases and cardiometabolic indications. Now an internal oligonucleotide platform within a major pharma — relevant incumbent comparable.
  • Sarepta Therapeutics: Commercial-stage RNA therapeutics company focused on gene therapy and exon-skipping PMO chemistries for Duchenne muscular dystrophy. Broader incumbent in RNA-based therapeutics with established commercial products and delivery expertise.

Regional players

  • Evotec: German drug discovery and development contract research organization with co-owned LNAplus™ antisense pipeline via Secarna partnership. Operating from Hamburg, Evotec is a comparable regional player with significant exposure to the oligonucleotide discovery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Secarna Pharmaceuticals social profiles

Digital presence

Secarna Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Secarna Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Secarna Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Secarna Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Secarna Pharmaceuticals

What does Secarna Pharmaceuticals do?

Secarna Pharmaceuticals discovers and develops antisense oligonucleotide (ASO) and siRNA therapeutics using its AI-empowered OligoCreator® platform, which combines innovative and proven delivery modalities with proprietary safety and efficacy testing systems. The company offers partnered drug discovery and co-development services to pharmaceutical, biotech, and academic organizations, while also advancing its own proprietary pipeline, including the lead clinical candidate SECN-15 targeting Neuropilin-1 (NRP1) for solid tumors. Secarna generates real lead candidates for partners within 6–12 months through single- or multi-asset collaboration agreements.

Is Secarna Pharmaceuticals a public or private company?

Secarna Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was Secarna Pharmaceuticals founded?

Secarna Pharmaceuticals was founded in 2015. It employs 11 to 50 people.

Where is Secarna Pharmaceuticals based?

Secarna Pharmaceuticals is headquartered in Martinsried, Germany, in the Europe region.

How does Secarna Pharmaceuticals make money?

Two revenue lines are on record. Partnership and Collaboration Agreements are the primary driver. The others are co-development and Co-ownership.

Who are Secarna Pharmaceuticals's main competitors?

Direct peers on record are Ionis Pharmaceuticals, Wave Life Sciences, Stoke Therapeutics, ProQR Therapeutics and Denali Therapeutics. Broad incumbents are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals (Novo Nordisk) and Sarepta Therapeutics. Evotec is listed as a regional player.

Does Secarna Pharmaceuticals have an API?

No public API is recorded for Secarna Pharmaceuticals.

What industry is Secarna Pharmaceuticals in?

Secarna Pharmaceuticals's product category is Antisense Oligonucleotide Drug Discovery. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageVERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) AllianceVERAXA Biotech and Secarna Pharmaceuticals announced initial positive results from their strategic collaboration to develop antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. Early in vitro studies showed that an AOC candidate combining both companies' technologies demonstrated greater potency than unconjugated oligonucleotides, leading the parties to discuss next steps in the alliance.BioSpaceVERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) AllianceVERAXA Biotech and Secarna Pharmaceuticals announced positive in vitro results from their collaboration on antibody oligonucleotide conjugates (AOCs). The AOC candidate showed greater potency than the unconjugated oligonucleotide, prompting discussions of next steps. The companies aim to explore AOCs for autoimmune and chronic immune diseases.The Pharma LetterSecarna Pharma and Curie.Bio expand partnershipSecarna Pharmaceuticals expanded its collaboration with Curie.Bio, announced in May 2025. The expansion includes Secarna's support in identifying oligonucleotide candidates using its proprietary OligoCreator platform for Curie.Bio's portfolio companies.GlobeNewswireVERAXA Biotech and Secarna PharmaceuticalsVERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop antibody oligonucleotide conjugates for autoimmune and chronic immune diseases. Secarna will use its OligoCreator platform, while VERAXA will apply its click chemistry conjugation technology. The partnership aims to combine their platforms for targeted therapies.VeraxaVeraxaVERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and inflammatory diseases, combining Secarna's AI-empowered OligoCreator® platform with VERAXA's click chemistry conjugation technology. The partnership aims to leverage the targeted delivery advantages of AOCs to precisely modulate gene expression in disease-relevant cells while minimizing off-target effects. Both companies expect the collaboration to open a wide range of therapeutic applications in immunology, building on VERAXA's existing focus in oncology and expanding Secarna's oligonucleotide expertise into new therapeutic modalities.GlobeNewswireSecarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS DisordersSecarna Pharmaceuticals and Vect-Horus announced a research collaboration to develop RNA-targeted therapeutics that cross the blood-brain barrier for CNS disorders. The partnership combines Vect-Horus' VECTrans delivery platform with Secarna's OligoCreator oligonucleotide discovery platform. The collaboration aims to advance treatments for neurodegenerative diseases.The Manila TimesSecarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS DisordersSecarna Pharmaceuticals and Vect-Horus announced a research collaboration to develop RNA-targeted therapeutics that cross the blood-brain barrier for CNS disorders. The partnership combines Vect-Horus' VECTrans delivery platform with Secarna's OligoCreator oligonucleotide discovery platform. The collaboration aims to advance treatments for neurodegenerative diseases.GlobeNewswireSecarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS DisordersSecarna Pharmaceuticals and Vect-Horus announced a strategic research collaboration to develop RNA-targeted therapeutics that cross the blood-brain barrier for CNS disorders. The partnership combines Vect-Horus' VECTrans delivery platform with Secarna's OligoCreator oligonucleotide discovery platform. The collaboration aims to advance treatments for neurodegenerative diseases.YahooSecarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS DisordersSecarna Pharmaceuticals and Vect-Horus announced a research collaboration to develop RNA-targeted therapeutics that cross the blood-brain barrier for CNS disorders. The partnership combines Vect-Horus' VECTrans delivery platform with Secarna's OligoCreator oligonucleotide discovery platform. The collaboration aims to advance treatments for neurodegenerative diseases.YahooSecarna Pharmaceuticals to Present New Data and Clinical Strategy for Lead Antisense Oligonucleotide Program SECN-15 at ASCO 2025Secarna Pharmaceuticals will present preclinical data on its lead antisense oligonucleotide SECN-15 at ASCO 2025, showing strong safety and anti-tumor activity in tumor models. The data support a planned Phase I/II trial for gastric cancer, targeting NRP1 to overcome ICI resistance.